On 26 June 2023, the rush to develop obesity therapies appeared to have raised the bar, as an experimental weight-loss drug from US pharma company Eli Lilly yielded the greatest effects of any treatment observed thus far.
The American Diabetes Association’s annual meeting has brought the competitive dynamics of obesity clinical development to the limelight after the data was presented on Lilly’s new obesity medication. Retatrutide – a Lilly product – has helped approximately 24% of people struggling with weight, the highest reported by any active drug. It targets GIP, GLP-1, and glucagon – a triple agonist.
The double-blind, randomized, placebo-controlled ...
